TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Not Specified
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

VYNE Therapeutics and Yarrow Bioscience have agreed to merge in an all-stock transaction, with Yarrow becoming the combined company. The merger will focus on advancing YB-101, a potential first-in-class antibody for treating Graves' disease and thyroid eye disease, supported by approximately $200 million in pre-closing private financings.

Insights
VYNE   neutral

Executing strategic alternative to maximize shareholder value, but will significantly reduce ownership in combined entity